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Gary H. Gibbons, MD*THE NATIONAL HEART, LUNG, AND
BLOOD INSTITUTE IN 2025: WHAT IF.I magine a world where we are able to prevent andpre-empt the burden of cardiovascular, lung, andblood diseases, a world where we are able to cap-
ture the promise of personalized precision medicine,
where each person receives the right treatment,
tailored to his or her needs, at the right time. In this
new world, what if we were able to realize a stroke-
free generation of individuals living with sickle cell
disease, what if we were able to eliminate health in-
equities (both domestic and global) with effective
and rapid uptake of evidence-based practices and
tools, and what if we could expand the frontiers of
scientiﬁc knowledge and revolutionize how we diag-
nose, prevent, and treat disease by leveraging the po-
wer of big scientiﬁc data systems? This vision is not
merely a collection of idle dreams; the boundless pos-
sibilities of this bold new world are well within our
reach.
BUILDING ON THE LEGACY OF SUCCESS
The mission of the National Heart, Lung, and Blood
Institute (NHLBI) is to enhance public health by
transforming research discoveries in heart, lung,
blood, and sleep (HLBS) systems into improved dis-
ease prevention and treatment. The NHLBI is building
on a history of research excellence by embarking on
a Strategic Visioning process to collectively identify
the greatest unmet needs in HLBS research. Our aimFrom the *National Heart, Lung, and Blood Institute, National Institutes
Institutes of Health, Bethesda, Maryland. The authors have reported that th
this paper to disclose.
Listen to this manuscript’s audio summary by JACC Editor-in-Chief Dr. Vale
You can also listen to this issue’s audio summary by JACC Editor-in-Chief Dis to engage all corners of the NHLBI community to
identify the most compelling scientiﬁc questions of
our time, questions that address pressing public
health challenges, capitalize on major advances in
technology, and take bold new approaches that,
because of their scope and complexity, transcend any
individual laboratory or organization, and require
NHLBI leadership (Figure 1). Investigator-initiated
research (e.g., R01 awards) makes up the majority
(z80%) of the NHLBI extramural budget. We have
every intention to maintain our high level of
commitment to investigator-initiated fundamental
discovery science; it is our top priority. This Strategic
Visioning process will largely inform our investments
that focus on NHLBI-initiated solicitations (e.g., re-
quests for applications, z20% of extramural research
funds) designed to catalyze the pursuit of in-
vestigations into important yet unexplored scientiﬁc
areas. Although the Strategic Visioning process will
guide institute-initiated activities, it may also provide
additional insights for individual investigator-
initiated programs.
For >60 years, the NHLBI community has fostered
a legacy of research excellence through ground-
breaking fundamental discovery science, landmark
clinical trials and population-based cohort studies,
and innovative health education and dissemination
efforts. For example, in the cardiovascular arena, the
Framingham Heart Study led to the identiﬁcation of
cholesterol as a major risk factor for heart disease (1).
Subsequent NHLBI-supported fundamental discovery
science identiﬁed pathways of cholesterol synthesisof Health, Bethesda, Maryland; and the yNational
ey have no relationships relevant to the contents of
ntin Fuster.
r. Valentin Fuster.
FIGURE 1 The Strategic Visioning Process Timeline for Community Engagement
The National Heart, Lung, and Blood Institute (NHLBI) Advisory Council and the Board of External Experts met jointly in September 2014 to create the initial outline for
the Strategic Visioning process. The NHLBI staff then developed a full Strategic Visioning Framework to elicit and collect scientiﬁc compelling questions (CQs) and critical
challenges (CCs) from the NHLBI community. In spring 2015, the entire NHLBI community will contribute CQs and CCs. These CQs and CCs will be reﬁned, integrated, and
evaluated against the NHLBI research portfolio to develop Draft Strategic Visioning Scientiﬁc Priorities, which will be released for public comment in summer 2015. The
NHBLI, working with its scientiﬁc advisory groups, will select a ﬁnal prioritized list of CQs and CCs and publish them as part of a Strategic Visioning Scientiﬁc Priorities
document by early 2016 that will describe the strategic priorities of the NHLBI.
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1131that paved the road for the development of statins (2),
a major contributor to the dramatic 75% reduction in
coronary heart disease since 1968 (3,4). Today, exome
sequencing technology is identifying rare genomic
variants such as those in the apolipoprotein C3
gene (APOC3) that result in lower triglyceride levels
and a lower risk of heart attack, which could lead
to the development of next-generation drugs that
can more effectively prevent heart disease (5).
Exciting new technologies are also changing how we
capitalize on these discoveries to arrest, or possibly
even reverse, disease pathobiology. For example, re-
searchers have developed high-density lipoprotein
nanoparticle carriers that can deliver statins directly
to atherosclerotic plaques and inhibit plaque pro-
gression or induce plaque regression (6).
Similarly, contributions of the lung research com-
munity continue to transform scientiﬁc advances into
better health. Research supported by the NHLBI on
chronic obstructive pulmonary disease, the third
most common cause of death in the United States, has
effectively enabled improved quality of life, allowing
patients to stay more active and slowing the pro-
gression of disease. However, not all patients with
similar exposures develop disease, and the variability
in disease severity and outcome poses several unan-
swered questions. The NHLBI is funding a number of
studies to better understand the heterogeneity, sus-
ceptibility, and progression of disease, analyzing
genomic, transcriptomic, imaging, microbiome, co-
morbidity, and biomarker data from large numbers of
subjects with varying levels of disease and mendelian
susceptibility to chronic obstructive pulmonarydisease. For example, investigators have recently
demonstrated that high-resolution computed to-
mography of the lung can facilitate the identiﬁcation
of certain lung pathologies well before the onset of
symptoms and before irreversible damage has
occurred (7). Integrating these data, we are learning
about multiple subphenotypes of chronic obstructive
pulmonary disease that appear to be both clinically
relevant and, in the case of some clusters, associated
with known genetic variants (8). Revealing the ge-
netic and physical characteristics underlying various
subtypes of chronic obstructive pulmonary disease
may enable the development of targeted, personal-
ized, and more effective early-stage therapeutic in-
terventions to pre-empt chronic disease.
Likewise, the blood research community has
improved the longevity and quality of life of patients
living with hematologic disorders and ensured the
safety of the donated blood supply. With the advent
of rapid, accurate tests to detect communicable blood
diseases, blood transfusions are safe for patients.
Research in blood systems has also established an
understanding of vascular trauma caused by sepsis,
malaria, and traumatic injury. Landmark clinical tri-
als established penicillin, blood transfusions, and
hydroxyurea as mainstay therapeutic options for the
management of sickle cell disease (9), mitigating
devastating complications of this disease. Today,
with the discovery of genetic regulators of fetal
hemoglobin such as BCL11a, gene editing tech-
niques to correct the sickle cell disease–causing mu-
tation, and new approaches to hematopoietic stem
cell transplantation, we are on the precipice of
FIGURE 2 Strateg
The Strategic Goals S
preventive and thera
From the National He
Institutes of Health,
Heart, Lung, and Blo
Lauer et al. J A C C V O L . 6 5 , N O . 1 1 , 2 0 1 5
NHLBI Strategic Visioning M A R C H 2 4 , 2 0 1 5 : 1 1 3 0 – 3
1132breakthroughs offering new therapeutic options or
even a cure for sickle cell disease.
Despite such major advances, cardiovascular and
respiratory diseases still pose a major health and
economic burden, accounting for 41% of all deaths
and 3 of the 4 leading causes of death in the United
States (10,11). Signiﬁcant health disparities exist
across racial/ethnic, age, sex, socioeconomic, and
geographic groups in diagnosis, prevention, and
treatment (12). Substantial lags exist in the translation
of research ﬁndings into products and practices that
could beneﬁt population health (13). There are, how-
ever, many exciting potential approaches to over-
coming these challenges, from the development of
rigorous dissemination and implementation research
approaches to shorten the evidence-to-practice lag in
clinical and public health settings; to the identiﬁcation
of novel multilevel strategies for improving care in
underserved vulnerable communities; to advances in
reparative biology, gene therapy, and nanotech-
nology; to the expanding application of computa-
tional power to perform systems biology analysis; to
the implementation of electronic medical records to
facilitate the delivery of personalized, predictive,
and pre-emptive clinical care. As public stewards for
advancing biomedical research, the NHLBI recog-
nizes the need to be forward looking, to proactively
leverage these scientiﬁc advances, and to support
the development of others as ways to tackle chal-
lenges and to signiﬁcantly accelerate the pace ofic Goals Supporting the NHLBI Mission
upporting the National Heart, Lung, and Blood Institute mission encompass un
peutic interventions, and developing a biomedical workforce with the necess
art, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (M
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od Institute, National Institutes of Health, or the U.S. Department of Healthresearch translation for maximal patient care
impact.
CHARTING OUR FUTURE TOGETHER:
THE NHLBI’s STRATEGIC VISIONING PROCESS
Through a robust and mission-driven portfolio of
research, training, and health education programs,
the NHLBI community has established the founda-
tion of research excellence that continues to turn
discovery science into improved health. The NHLBI
Strategic Visioning process will begin the launch of a
new research agenda for the next decade by identi-
fying bold and mission-critical questions and chal-
lenges in basic, clinical, translational, and population
science related to HLBS disorders. We invite you to
chart this future with us through a Strategic Visioning
process that is open, inclusive, and iterative and
draws on your creativity. This process is designed to
build on our existing Strategic Plan (14) by inviting
the entire NHLBI community to share ideas for
addressing future research and workforce needs.
PROVIDE YOUR PERSPECTIVE AND EXPERTISE
A major innovative feature of the Strategic Visioning
process is the active, iterative, and grassroots
engagement of the NHLBI community to identify bold
and compelling scientiﬁc questions that NHLBI needs
to address to promote HLBS health of all individuals.derstanding human health and disease, translating basic research into
ary skills and tools for heart, lung, blood, and sleep (HLBS) research.
.S.L., J.P.K., S.C.M., G.A.M., W.K.H., Y.P., N.L.C., G.H.G.); and National
the authors and do not necessarily represent the views of the National
and Human Services.
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1133As accountable stewards of the public’s investment,
we are striving for an inclusive process engaging a
broad circle of partners, including scientists, medical
professionals, policy makers, patients and patient
advocates, professional groups, and the general
public. Exercise your imagination and apply your
expertise through this Strategic Visioning process—
think big, bold, and creative ideas—and know that
your voice and the voices of your colleagues will be
heard. With the beneﬁt of these diverse perspectives
that provide insights, solutions, and concerns, the
NHLBI will be well positioned to understand the
needs of the NHLBI community as it plans for future
institute-initiated activities.
The NHLBI’s mission-driven strategic goals
(Figure 2) broadly address basic, clinical, population,
and public health research in HLBS systems in health
and disease; expedite translational research; and
promote the development of a biomedical workforce
with skills and tools to pursue these goals, all to
advance knowledge that enhances the prevention,
treatment, and cure of HLBS disorders. The ideas
submitted should be related to the 4 strategic goals
and identify important gaps in knowledge (referred
to as compelling questions) or new opportunities
to overcome major barriers to progress (referred to
as critical challenges) that require facilitation by
the NHLBI.
The NHLBI has released a Strategic Visioning
Framework that outlines this process in more detail
and invites the community to participate (15). The
community can now submit compelling questionsand critical challenges over the next 4 months
using an interactive feature on our new Web
site specially dedicated to the Strategic Visioning
process (http://strategicvisioning.nhlbi.nih.gov or
e-mail nhlbi_vision@mail.nih.gov). These questions
and challenges will then be reviewed, reﬁned, syn-
thesized, and assessed against the current NHLBI
research portfolio to help shape the Draft Strategic
Visioning Scientiﬁc Priorities, which will be released
for public comment in mid-2015. Using public com-
ments and key prioritization considerations, the
NHLBI, working with its scientiﬁc advisory groups,
will prioritize the compelling questions and critical
challenges within each strategic goal. This process
will result in the Strategic Visioning Scientiﬁc Prior-
ities, which will be released in ﬁnal form to the public
by early 2016 and will describe the most pressing
knowledge gaps and exciting prospects for advances
in HLBS health.
The strategic priorities that emerge from this pro-
cess will serve as a “living GPS [global positioning
system] guide” for NHLBI activities for the future.
Together, let us design the path that will lead to a
world with dramatically improved prevention, diag-
nosis, and treatment of HLBS diseases.
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